About Rho GTPase-activating protein 1
Rho GTPase-activating protein 1 (ARHGAP1) is a protein
from Homo sapiens identified by UniProt accession
Q07960, 439 residues long.
MolForge cross-references it against 0 known binders and
128 disease associations.
Target properties
| Protein name | Rho GTPase-activating protein 1 |
| UniProt accession | Q07960 |
| Gene | ARHGAP1 |
| Organism | Homo sapiens |
| Length | 439 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (128)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.32
- Parkinson disease · score 0.22
- Alzheimer disease · score 0.22
- multiple sclerosis · score 0.22
- lysosomal storage disease · score 0.22
- glucose measurement · score 0.18
- insulin measurement · score 0.16
- Familial exudative vitreoretinopathy · score 0.14
- cor pulmonale · score 0.11
- femoral neck bone mineral density · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q07960-F1 | alphafold | PREDICTED | 82.02 | — |
Amino-acid sequence (439 residues)
MDPLSELQDD LTLDDTSEAL NQLKLASIDE KNWPSDEMPD FPKSDDSKSS SPELVTHLKW DDPYYDIARH QIVEVAGDDK YGRKIIVFSA CRMPPSHQLD HSKLLGYLKH TLDQYVESDY TLLYLHHGLT SDNKPSLSWL RDAYREFDRK YKKNIKALYI VHPTMFIKTL LILFKPLISF KFGQKIFYVN YLSELSEHVK LEQLGIPRQV LKYDDFLKST QKSPATAPKP MPPRPPLPNQ QFGVSLQHLQ EKNPEQEPIP IVLRETVAYL QAHALTTEGI FRRSANTQVV REVQQKYNMG LPVDFDQYNE LHLPAVILKT FLRELPEPLL TFDLYPHVVG FLNIDESQRV PATLQVLQTL PEENYQVLRF LTAFLVQISA HSDQNKMTNT NLAVVFGPNL LWAKDAAITL KAINPINTFT KFLLDHQGEL FPSPDPSGL
Explore Rho GTPase-activating protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets